PURPOSE: To evaluate the impact of highly active antiretroviral therapy (HAART) on cancer incidence in HIV-infected children throughout a 20-year period. PATIENTS AND METHODS: An observational population study was conducted on 1,190 perinatally HIV-infected children enrolled onto the Italian Register for HIV Infection in Children from 1985 to 2004 and never lost to follow-up (total observation time, 10,037.66 years). Cancer rates were calculated in the pre-HAART (1985 to 1995), early HAART (1996 to 1999), and late HAART (2000 to 2004) periods and compared using Poisson regression adjusted for age. The proportion of HAART-treated children increased from 4.1% in 1996 to 60.4% in 1999 and to 81.5% in 2004. In the same time frame, the proportion of children receiving HAART for at least 2 years increased from 3.1% to 77.0%. RESULTS: Overall, 35 cancers occurred. Cancer rates were 4.49 (95% CI, 2.37 to 6.64), 4.09 (95% CI, 1.68 to 6.50), and 0.76 (95% CI, 0.00 to 1.80) per 1,000 children per year in 1985 to 1995, 1996 to 1999, and 2000 to 2004, respectively. Notably, there was no significant difference comparing the periods from 1985 to 1995 and 1996 to 1999 (P = .081). By contrast, cancer rates were significantly lower in the period from 2000 to 2004 than in 1996 to 1999 (P < .0001). Results were confirmed by separately analyzing data from children observed from birth (P = .418 for 1985 to 1995 v 1996 to 1999; P = .001 for 1996 to 1999 v 2000 to 2004). CONCLUSION: Dramatically reduced cancer rates were observed only in the late HAART period in parallel to the increasing proportion of children receiving HAART therapy.

Cancer rates after year 2000 significantly decrease in children with perinatal HIV infection: A study by the Italian Register for HIV Infection in Children

BEZZI, Teresa Maria;FIUMANA, Elisa;
2007

Abstract

PURPOSE: To evaluate the impact of highly active antiretroviral therapy (HAART) on cancer incidence in HIV-infected children throughout a 20-year period. PATIENTS AND METHODS: An observational population study was conducted on 1,190 perinatally HIV-infected children enrolled onto the Italian Register for HIV Infection in Children from 1985 to 2004 and never lost to follow-up (total observation time, 10,037.66 years). Cancer rates were calculated in the pre-HAART (1985 to 1995), early HAART (1996 to 1999), and late HAART (2000 to 2004) periods and compared using Poisson regression adjusted for age. The proportion of HAART-treated children increased from 4.1% in 1996 to 60.4% in 1999 and to 81.5% in 2004. In the same time frame, the proportion of children receiving HAART for at least 2 years increased from 3.1% to 77.0%. RESULTS: Overall, 35 cancers occurred. Cancer rates were 4.49 (95% CI, 2.37 to 6.64), 4.09 (95% CI, 1.68 to 6.50), and 0.76 (95% CI, 0.00 to 1.80) per 1,000 children per year in 1985 to 1995, 1996 to 1999, and 2000 to 2004, respectively. Notably, there was no significant difference comparing the periods from 1985 to 1995 and 1996 to 1999 (P = .081). By contrast, cancer rates were significantly lower in the period from 2000 to 2004 than in 1996 to 1999 (P < .0001). Results were confirmed by separately analyzing data from children observed from birth (P = .418 for 1985 to 1995 v 1996 to 1999; P = .001 for 1996 to 1999 v 2000 to 2004). CONCLUSION: Dramatically reduced cancer rates were observed only in the late HAART period in parallel to the increasing proportion of children receiving HAART therapy.
2007
Chiappini, E; Galli, L; Tovo, Pa; Gabiano, C; Lisi, C; Giaquinto, C; Rampon, O; Gattinara, Gc; De Marco, G; Osimani, P; Manzionna, M; Miniaci, A; Pintor, C; Rosso, R; Esposito, S; Viganò, A; Dodi, I; Maccabruni, A; Fundarò, C; de Martino, M; P., Osimani; R., Cordiali; D., De Mattia; M., Manzionna; C., Di Bari; M., Ruggeri; M., Masi; A., Miniaci; F., Specchia; M., Ciccia; M., Lanari; F., Baldi; L., Battisti; C., Fiorino; C., Dessı`; C., Pintor; M., Dedoni; M. L., Fenu; R., Cavallini; E., Anastasio; F., Merolla; M., Sticca; G., Pomero; Bezzi, Teresa Maria; Fiumana, Elisa; F., Bonsignori; P., Gervaso; E., Seini; M. T., Cecchi; D., Cosso; A., Timitilli; M., Stronati; A., Plebani; R., Pinzani; I., Bongianin; A., Vigano`; V., Giacomet; P., Erba; F., Salvini; G. V., Zuccotti; M., Giovannini; G., Ferraris; R., Lipreri; C., Moretti; M., Cellini; M. C., Cano; P., Paolucci; E., Bruzzese; G., De Marco; L., Tarallo; F., Tancredi; M., Pennazzato; O., Rampon; E. R., Dalle Nogare; A., Sanfilippo; A., Romano; M., Saitta; I., Dodi; A., Barone; A., Maccabruni; R., Consolini; A., Legitimo; C., Magnani; P., Falconieri; C., Fundaro`; O., Genovese; A., Panzanella; A. M., Casadei; A., Martino; C., Concato; G., Anzidei; G., Bove; S., Cerilli; S., Catania; C., Ajassa; A., Ganau; L., Cristiano; A., Mazza; A., Di Palma; F., Mignone; C., Riva; C., Scorfaro; V., Portelli; M., Rabusin; A., Pellegatta; M., Molesini
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/524120
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 23
social impact